drugset / Trial / NCT02060019

Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects

NCT02060019

Phase 1 Completed 57 enrolled HK inno.N Corporation
Non-randomizedCrossoverOpen-labelBasic science

Summary

This study is designated to evaluate the pharmacokinetic interactions of amlodipine besylate, valsartan and rosuvastatin in healthy male volunteers.

Timeline

Start
2014-03
Primary completion
2014-06
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 10 mg
Subject Rosuvastatin Small molecule 20 mg
Subject Valsartan Small molecule 160 mg

Indications

No indication recorded.